Protective effect of acellular pertussis vaccines
Two acellular pertussis vaccines, a mono-component toxoid of pertussis toxin and a two-component vaccine containing both the toxoid and filamentous haemagglutinin, were used for primary immunization of infants 5 1/2 to 10 months of age in two clinical trials in Sweden. Over a follow-up period of 12 to 17 months, 37 children were exposed to pertussis in the household or a daycare centre. Only one child developed mild, culture-confirmed pertussis as opposed to the expected number of 30 to 33 cases based on an assumed attack rate of 80–90% in non-immunized children. These preliminary findings indicate that, given as primary immunization to infants, the vaccines provide protection against pertussis.
KeywordsClinical Trial Internal Medicine Protective Effect Pertussis Preliminary Finding
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Reviews of Infectious Diseases 1979, 1: 401–412.Google Scholar
Robinson, A., Irons, L. I., Ashworth, L. A.
Pertussis vaccine: present status and future prospects. Vaccine 1985, 3: 11–22.CrossRefPubMedGoogle Scholar
Manclark, C. R., Burns, D. L.
Prospects for a new acellular pertussis vaccine. Annales de Microbiologie 1985, 136: 323–329.Google Scholar
Sato, Y., Kimura, M., Fukumi, H.
Development of a pertussis component vaccine in Japan. Lancet 1984, i: 122–126.CrossRefGoogle Scholar
Aoyama, T., Murase, Y., Kato, T., Iwata, T.
Efficacy of an acellular pertussis vaccine in Japan. Journal of Pediatrics 1985, 107: 180–183.PubMedGoogle Scholar
Blennow, M., Granström, M., Olin, P., Tiru, M., Jäätmaa, E., Askelöf, P., Sato, Y.
Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, JNIH-6. Developments in Biological Standardization 1986, 65: 185–190.PubMedGoogle Scholar
Hedenskog, S., Granström, M., Olin, P., Tiru, M., Sato, Y.
A clinical trial of a monocomponent pertussis toxoid vaccine. American Journal of Diseases of Children 1987, 141: 844–847.PubMedGoogle Scholar
Granström, M., Granström, G., Gillenius, P., Askelöf, P.
Neutralizing antibodies to pertussis toxin in whooping cough. Journal of Infectious Diseases 1985, 151: 646–649.PubMedGoogle Scholar
Granström, M., Granström, G., Lindfors, A., Askelöf, P.
Serologic diagnosis of whooping cough by an enzyme-linked immunosorbent assay using fimbrial hemagglutinin as antigen. Journal of Infectious Diseases 1982, 146: 741–745.PubMedGoogle Scholar
Daniel, W. W.
Biostatistics: a foundation for analysis in the health sciences. John Wiley and Sons, New York, 1983, p. 66–73.Google Scholar
Lapin, J. H.
Whooping cough. Charles C. Thomas, Springfield, 1943, p. 8–9.Google Scholar
Medical Research Council
The prevention of whooping-cough by vaccination. British Medical Journal 1951, i: 1463–1471.Google Scholar
Broome, C. V., Preblud, S. R., Bruner, B., McGowan, J. E., Hayes, P. S., Harris, P. P., Elsea, W., Fraser, D. W.
Epidemiology of pertussis, Atlanta, 1977. Journal of Pediatrics 1981, 98: 362–367.PubMedGoogle Scholar
Noble, G., Bernier, R., Esber, E. C., Hardegree, M. C., Hinman, A. R., Klein, D., Saah, A. J.
Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists. Journal of the American Medical Association 1987, 257: 1351–1356.CrossRefPubMedGoogle Scholar
Respiratory illness in preschool children with different forms of day care. Pediatrics 1976, 57: 191–196.PubMedGoogle Scholar
© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1988